Key result
Angiotensin II as a primary vasopressor in vasodilatory hypotension was associated with lower ICU mortality compared to conventional vasopressors (10% vs 26%, P=0.04).
Why the study?
The study was conducted to evaluate the efficacy and safety of using angiotensin II as a primary vasopressor for vasodilatory hypotension in critically ill adults.
Does angiotensin II as a primary vasopressor improve clinical and renal outcomes in critically ill adults with vasodilatory hypotension compared to conventional vasopressors?
Comparison
Angiotensin II as primary vasopressor vs conventional vasopressors
Design
Prospective observational matched-control pilot study
Follow-up
90 days
Authors
Loading...
Ang2 as primary vasopressor in vasodilatory shock is hypothesis-generating; leaves open its comparative efficacy and safety versus conventional agents.
Observational (n=120)
No
Does angiotensin II as a primary vasopressor improve clinical and renal outcomes in critically ill adults with vasodilatory hypotension compared to conventional vasopressors?
Absolute Event Rate: 10% vs 26%
p-value: p=0.04
In critically ill adults with vasodilatory hypotension, primary use of angiotensin II was associated with lower ICU mortality and fewer troponin elevations compared to conventional vasopressors, though it did not significantly improve overall renal outcomes or 90-day survival.
See et al. (2023) conducted an observational in Vasodilatory hypotension (n=120). Angiotensin II (Ang2) vs. Conventional vasopressors (norepinephrine, vasopressin, metaraminol, epinephrine, or combinations) was evaluated on ICU mortality (p=0.04). Angiotensin II as a primary vasopressor in vasodilatory hypotension was associated with lower ICU mortality compared to conventional vasopressors (10% vs 26%, P=0.04).
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: